GlassScriptPhysician profile
Lee Scott Wesler
NPI 1982766325
$22,580.10
in general payments reported to CMS, 2019-2025
62 companies · $4,444 in 2025
The $4,444 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,004 · 2020: $1,644 · 2021: $3,202 · 2022: $3,161 · 2023: $3,612 · 2024: $3,513 · 2025: $4,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,090.22 |
| Education | $478.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,313.15 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,871.99 | 2019-2025 | Tezspire, Farxiga, Breztri |
| Teva Pharmaceuticals USA, INC. | $1,796.79 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novo Nordisk INC | $1,760.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,700.73 | 2019-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $1,421.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corcept Therapeutics | $1,312.39 | 2021-2025 | Korlym |
| Lilly USA, LLC | $784.76 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $732.32 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $725.38 | 2019-2025 | Rexulti, Jynarque |
| Xeris Pharmaceuticals, INC. | $667.29 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $642.05 | 2020-2025 | Caplyta |
| Amgen INC. | $618.09 | 2019-2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $546.91 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $496.72 | 2019-2022 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Wesler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.